MedTrace Logo

Effect of Thrombolysis on 30-day Mortality in Intermediate High Risk Pulmonary Patients With Low Bleeding Risk

NCT07374978 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2026-01-29

No results posted yet for this study

Summary

The aim of investigators was to study the effect and safety of Thrombolysis in Intermediate high risk pulmonary embolism patients with low bleeding risk as regards Mortality and bleeding events.

Conditions

  • Pulmonary Embolism Subacute Massive
  • Thrombolytic Therapy

Interventions

DRUG

Thrombolytic therapy for the study group in the form of streptokinase or recombinant tissue plasminogen activator

Thrombolytic therapy acting on thrombus in pulmonary embolism patients

DRUG

Unfractionated Heparin IV

Standard anticoagulation

Sponsors & Collaborators

  • Ain Shams University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
25 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-07-01
Primary Completion
2025-05-01
Completion
2025-07-01

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07374978 on ClinicalTrials.gov